Abstract 192P
Background
Studies of apatinib monotherapy suggest that ARAE (proteinuria, hand-foot syndrome [HFS] and hypertension) may predict clinical outcomes in patients with AGC; however, this phenomenon has not been reported in patients receiving apatinib + chemotherapy. We evaluated the potential association between ARAE and efficacy outcomes of apatinib +chemotherapy for AGC.
Methods
We reviewed two prospective trials of patients treated with apatinib + chemotherapy (POF or paclitaxel alone), a phase II study (ESMO-ASIA 2018) and a phase I study (ESMO 2022). POF was paclitaxel 135 mg/m2 over 3 h followed by leucovorin 400 mg/m2 and oxaliplatin 85 mg/m2 over 2 h; then 5-FU 2,400 mg/m2 continuous infusion over 46 h. Drugs were started days 1 and 15 of each 28-day cycle. Paclitaxel alone was 80 mg/m2 days 1, 8, and 15 of every 28-day cycle. Presence of any ARAE in the first 4 weeks of therapy was assessed and the primary outcome was overall survival (OS). OS was estimated using Kaplan-Meier with the log-rank test. Hazard ratios (HRs) were calculated by univariate and multivariate Cox proportional regression models.
Results
The number of participants was 43 (POF, n=41; paclitaxel alone, n=2). In the first 4 weeks of treatment, 22 (51.2%) had any grade proteinuria, 13 (30.0%) had any grade HFS, and 14 (32.6%) had any grade hypertension. The presence of proteinuria or HFS was associated with prolonged median OS ([months] proteinuria 5.93 vs. 19.10; HR 0.40, 95% CI 0.20-0.79; P=0.0065; HFS 8.92 vs. 22.57 ; HR 0.48, 95% CI 0.23-0.98; P=0.04) and progression-free survival ([PFS] proteinuria 3.50 vs. 9.60 ; HR 0.46, 95% CI 0.23-0.91; P=0.022; HFS 6.40 vs. 10.67 ; HR 0.54, 95% confidence interval (CI) 0.27-1.07; P=0.073 ). 24 (55.8%) patients had one (any grade) proteinuria or HFS in the first 4 weeks, which was associated with prolonged median OS (6.77 vs. 16.35 ; HR 0.47, 95% CI 0.24-0.93; P=0.031) and PFS (4.20 vs. 8.75; HR 0.55, 95% CI 0.28-1.08; P=0.080).
Conclusions
Antiangiogenesis-related proteinuria and HFS may be biomarkers to predict antitumor efficacy of apatinib + chemotherapy in AGC. Future prospective studies are needed to validate findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
383P - Pre-treatment body mass index and neutrophil lymphocyte ratio predict 3-years progression free survival in locally advanced stage nasopharyngeal carcinoma
Presenter: Ni Putu Pusvita Dewi
Session: Poster Display
Resources:
Abstract
384P - Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan
Presenter: Wei-Chen Lu
Session: Poster Display
Resources:
Abstract
385P - The prognostic factors of induction chemotherapy followed by concurrent chemoradiotherapy in patients with HPV associated with oropharyngeal cancer
Presenter: Hyun Jin Bang
Session: Poster Display
Resources:
Abstract
386P - FOLR1 stabilized beta-catenin promotes laryngeal carcinoma progression through EGFR signal
Presenter: Huawei Tuo
Session: Poster Display
Resources:
Abstract
387P - A comprehensive analysis of the oral health status, tobacco use, and cancer prevalence among the tribal communities in India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
388P - Clinicopathological correlation of P53 expression in oral cancers
Presenter: Venkata Madhavi Bellala
Session: Poster Display
Resources:
Abstract
389P - Lack of cross-resistance to erlotinib in human head and neck cancer cells with acquired resistance to cetuximab
Presenter: James A. Bonner
Session: Poster Display
Resources:
Abstract
390P - Epidemiological aspects of the development of oral cancer in the Republic of Uzbekistan
Presenter: Akhrorbek Yusupbekov
Session: Poster Display
Resources:
Abstract
391P - Lip cancer: Racial disparities, treatment modalities and long-term survival outcome in young and adults versus older age patients
Presenter: FathAlrahman Ibrahim
Session: Poster Display
Resources:
Abstract
392TiP - A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy
Presenter: Juyi Wen
Session: Poster Display
Resources:
Abstract